Orchestra BioMed Holdings (OBIO) EBIT Margin (2022 - 2026)
Orchestra BioMed Holdings (OBIO) reported EBIT Margin of 20069.09% for Q1 2026, down 1788925.0% year-over-year from N/an in Q1 2025, and down 91967.94% on a QoQ basis from 21.85% in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 5 years of EBIT Margin data on file, last reported at 20069.09% in Q1 2026.
- Quarterly EBIT Margin fell 1788925.0% year-over-year to 20069.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 167.96% (up 221593.0% YoY) and the FY2025 annual result came in at 154.73%, up 228276.0% from the prior year.
- EBIT Margin declined to 20069.09% in Q1 2026 per OBIO's latest filing, from 21.85% in the prior quarter.
- Across five years, EBIT Margin topped out at 21.85% in Q4 2025 and bottomed at 20069.09% in Q1 2026.
- The 5-year median for EBIT Margin is 2166.97% (2024), against an average of 3207.6%.
- The widest annual swing landed in 2025, when EBIT Margin surged 661355 bps; it then plunged 1788925 bps in 2026.
- Tracing OBIO's EBIT Margin over 5 years: stood at 891.02% in 2022, then sank by 435 bps to 4763.74% in 2023, then plunged by 38 bps to 6591.7% in 2024, then surged by 100 bps to 21.85% in 2025, then sank by 91968 bps to 20069.09% in 2026.
- Per Business Quant, the three latest OBIO EBIT Margin figures stand at 20069.09% (Q1 2026), 21.85% (Q4 2025), and 2359.23% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -20,069.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,069.09% |
| Dec 31, 2025 | 21.85% |
| Sep 30, 2025 | -2,359.23% |
| Jun 30, 2025 | -2,311.84% |
| Mar 31, 2025 | -2,179.84% |
| Dec 31, 2024 | -6,591.70% |
| Sep 30, 2024 | -1,655.72% |
| Jun 30, 2024 | -2,166.97% |
| Mar 31, 2024 | -2,326.29% |
| Dec 31, 2023 | -4,763.74% |
| Sep 30, 2023 | -3,466.35% |
| Jun 30, 2023 | -1,415.96% |
| Mar 31, 2023 | -991.84% |
| Dec 31, 2022 | -891.02% |
| Sep 30, 2022 | -865.61% |
| Jun 30, 2022 | -1,903.74% |
| Mar 31, 2022 | -592.15% |